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1. Introduction 
Pancreatitis is the most common complication of endoscopic retrograde 
cholangiopancreatography (ERCP) [1–4]. The reported incidence ranges from 1.8% to 7.2% in 
most prospective series [5–9] but can be up to 30%, depending on the criteria used to diagnose 
pancreatitis, the type and duration of patient follow-up, and the type of case mix [10]. More 
commonly, hyperamylasemia occurs in up to 30% of patients undergoing ERCP [11]. 
As the indications for ERCP have increased, a greater focus on recognizing and preventing 
complications has emerged. The recognized complications of ERCP include asymptomatic 
hyperamylasemia, cardiopulmonary depression, hypoxia, aspiration, intestinal perforation, 
bleeding, cholangitis, adverse medication reactions, sepsis, acute pancreatitis, and death. 
Post-ERCP pancreatitis (PEP) remains the leading cause of morbidity and mortality after the 
procedure and is the focus of studies designed to improve procedural outcomes [12,13]. 
Some studies have suggested that the rates of PEP can be reduced, but the incidence of 
pancreatitis remains high particularly in at-risk patient populations. Pancreatitis continues 
to be the major cause of postprocedure morbidity and mortality [14–17]. 
2. Diagnosis of PEP  
PEP was defined initially as the presence of new pancreatic-type abdominal pain associated 
with at least a threefold increase in serum amylase concentration occurring 24 h after an 
ERCP, with pain severe enough to require admission to the hospital or to extend an 
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admitted patient’s length of stay. This definition was developed in 1991 based upon 
approximately 15 000 procedures evaluated during a consensus workshop. The severity of 
PEP was defined according to the length of stay (mild pancreatitis 2–3 d, moderate 
pancreatitis 4–10 d, and severe pancreatitis >10 d, or intensive care admission or local 
complications secondary to pancreatitis) [18]. This consensus definition has not been 
adopted uniformly and many studies published after 1991 have used different criteria to 
define PEP and to classify its severity. Several studies have challenged the serum amylase 
threshold of three times the upper limit of normal, arguing that this definition is not always 
consistent with the clinical and morphological features of pancreatitis [19–25]. Other criteria 
for serum amylase elevation include twice [23–26], four times [6,27,28] and five times 
[20,21,28–30] the upper normal limit. 
There is also heterogeneity in the criteria used to classify the severity of PEP in published 
studies. Some authors have used the Atlanta criteria published in 1993 to define severity 
[31–33]. The Atlanta criteria incorporate systemic complications of PEP by integrating the 
Acute Physiologic and Chronic Health Evaluation (APACHE) II classification and Ranson’s 
criteria to define the severity [33–35]. An APACHE II score of >8 or a Ranson’s score of 3 of 
11 criteria are defined as severe PEP. Some studies have used the APACHE II classification 
alone to grade the severity of PEP [36]. Other studies have used combinations of criteria to 
define the presence and severity of PEP or have established unique definitions [26,31,37–40]. 
The heterogeneity of criteria in the literature on PEP hinders direct comparison of the 
published clinical trials. 
3. Pathophysiology of PEP 
The pathophysiology of PEP is not well understood. Mechanical, hydrostatic, chemical, 
enzymatic, allergic, thermal, cytokine, oxidative, and microbiological factors have all been 
proposed as causes [32,41–46]. Many studies suggest that PEP results from mechanical 
trauma, causing injury to the papilla or pancreatic sphincter and subsequent swelling of 
the pancreatic duct and obstruction to the flow of pancreatic enzymes. This hypothesis 
remains controversial, and no consensus about the pathogenesis of PEP has been 
established. 
The cascade of events leading to acute pancreatitis is characterized by three phases. The first 
phase is characterized by premature activation of trypsin within the pancreatic acinar cells 
[47]. The second phase is characterized by intrapancreatic inflammation. The third phase is 
characterized by extrapancreatic inflammation [47]. Inflammation in the second and third 
phases has been described as a four-step process: (1) activation of inflammatory cells; (2) 
chemoattraction of activated inflammatory cells; (3) activation of adhesion molecules 
causing binding of inflammatory cells to the endothelium; and (4) migration of activated 
inflammatory cells into areas of inflammation [47]. Recent studies have evaluated 
proinflammatory markers (TNF, interleukin-1 (IL-1), IL-6, IL-8, PAF, and IL-10) in the 
setting of PEP [48–51]. Although three randomized controlled trials (RCTs) suggested a 
protective effect of low- or high-dose (4 g/kg or 20 g/kg) IL-10 given intravenously 15–30 
min before ERCP [52], subsequent studies using similar IL-10 protocols did not support 
these findings [53,54]. Although not demonstrated at present, modulation of 
proinflammatory pathways might be an appealing goal for studies evaluating PEP and the 
systemic inflammatory response. 
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4. Procedural-related factors associates with PEP 
Although the triggers of the inflammatory cascade are not well understood, procedural- and 
patient-related factors have been clearly associated with the incidence of PEP. ERCP is the 
most technically difficult endoscopic procedure performed by trainees and experienced 
endoscopists in both inpatient and outpatient settings. Whereas trauma to the duodenum or 
papilla during endoscopy without cannulation rarely causes pancreatitis [55], cannulation of 
the papilla, especially in moderate to difficult cases, is associated with high rates of PEP. 
Procedures involving multiple (>1–4) or failed attempts at cannulation, multiple pancreatic 
injections (2–5), pancreatic acinarization, and prolonged cannulation time (>10 min) are 
associated with PEP. The following factors have also been associated with a higher risk for 
developing PEP: operator experience, ampullary balloon dilation, precut access 
sphincterotomy, endoscopic sphincterotomy (ES), sphincter of Oddi manometry, distal 
common bile duct diameters of 1 cm, presence of a pancreatic stricture, papillectomy, and 
procedures not involving stone removal [45,56–59] (Table 1). 
 
Patient related  
factors 
Young age. 
Female gender. 
Suspected sphincter of Oddi dysfunction. Recurrent 
pancreatitis. 
Prior history of post-ERCP pancreatitis. 
Patients with normal serum bilirubin. 
Procedure related factors 
Multiple pancreatic duct injections. 
Difficult cannulation. 
Pancreatic sphincterotomy. 
Precut access. 
Balloon dilation. 
Operator/technical related 
factors 
Inadequate training and/or experience 
Trainee involvement in procedure 
Table 1. Factors Increasing the Risk of Post-ERCP Pancreatitis. 
4.1 Operator experience 
Although there is no established mandate for the procedure volume to develop competence 
in ERCP, a prospective study published in 1996 evaluated the number of supervised ERCPs 
a physician must perform to achieve procedural competence and reported that at least 180 
procedures are required [60]. In the United States, the American Society for Gastrointestinal 
Endoscopy and the American College of Gastroenterology have published quality indicators 
for ERCP. Competent endoscopists are expected to be able to perform sphincterotomy, clear 
the common bile duct of stones, provide relief of biliary obstruction, and successfully place 
stents for bile leaks in 85% of patients [61]. 
Few studies have been published on operator experience in ERCP, and this issue remains 
controversial. A recent study in Austria showed that a case volume of >50 ERCPs per year 
had higher success and lower overall complication rates [62]. It is generally agreed that the 
case mix at high volume and in academic referral centers may include a larger proportion of 
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difficult and high-risk cases, which may confound the relationship between experience and 
complication rates. Although operator experience is felt to be critical for high-quality 
outcomes, many large prospective and retrospective trials have not shown consistent 
correlations between inexperience and PEP. Higher rates of bleeding have been reported 
after endoscopic sphincterotomy with a mean case volume of <1 per wk [14], and trainee 
involvement was associated with severe or fatal complications in a recent retrospective 
analysis [63]. However, a large prospective trial found that case volume had no effect on the 
incidence of PEP [24]. A prospective study of ERCP in the United Kingdom (UK) in 2007 
based on self-reported surveys demonstrated that 15% of all credentialed endoscopists 
performed <50 ERCPs per year compared with 61% of those in training; 11% of deaths 
occurred after procedures by endoscopists who performed <50 ERCPs per year. Although 
the rates of PEP were low at 1.5%, the success rates for bile duct stone extraction and biliary 
stent placement were 62% and 73%, respectively. The authors concluded that in the UK 
there is a need for fewer operators and greater experience in those performing therapeutic 
endoscopy [64]. In the same year, a study in France showed no risk associated with operator 
inexperience [65]. 
4.2 Cannulation techniques 
Cannulation techniques to access the pancreatic and biliary ducts include the use of a 
sphincterotome or straight or curved catheter with guide wires or contrast injection. When 
an initial attempt at cannulation fails, access may be achieved after placement of a 
pancreatic guide wire or stent to help guide the endoscopist toward the common bile duct 
and away from the pancreatic duct. Precut access papillotomy is used frequently in referral 
centers when conventional approaches fail. Rare or experimental techniques such as the use 
of endoscopic scissors or endoscopic dissection with a cotton swab have been reported but 
are used rarely in clinical practice [66]. 
Compared with a standard catheter, the use of a sphincterotome may decrease the number 
of failed attempts to obtain biliary access, the time required to cannulate the common bile 
duct, and the rate of PEP [67,68]. Selective sphincterotome cannulation with a guide wire 
may reduce the rate of PEP compared with cannulation with contrast injection [67–71]. In 
2008, a large prospective controlled trial randomized 430 patients into sphincterotome plus 
guide wire versus conventional cannulation arms. The series demonstrated a significantly 
higher rate of cannulation with guide wires but failed to show a significant difference in the 
rate of PEP between the two approaches [72]. The authors reported an 8.8%–14.9% increased 
risk of PEP after >4 attempts at the papilla, highlighting the importance of cannulation with 
fewer attempts. These findings are consistent with those of previous studies [7,72]. 
4.3 Pancreatic duct injection  
Multiple pancreatic duct injections (2–5) [6,7,15,24,58] and pancreatic acinarization 
[6,12,15,30] are recognized as risk factors for PEP. Differences in the osmolality and ionicity 
of contrast media have been studied with varying results in terms of impact on PEP 
[25,28,59,73–75]. A recent meta-analysis of 13 RCTs found no significant difference between 
high- and low-osmolality contrast media [75]. Earlier studies suggested that there is a 
decreased risk of PEP with the use of nonionic contrast agents [73], although this has not 
been demonstrated consistently [74]. One large retrospective analysis of 14 331 ERCPs 
suggested that less opacification of the pancreatic duct in the head than in the tail produced 
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significantly lower rates of PEP [59]. Despite the variable findings, clinical trial data suggest 
that hydrostatic pressure may play a role in the development of pancreatitis. 
4.4 Pancreatic duct stenting  
The theory that PEP is caused by pancreatic duct obstruction is supported by most RCTs, 
which show a decreased incidence of pancreatitis in high-risk patients after placement of a 
pancreatic duct stent [76–84]. The three largest published studies to evaluate the rate of 
pancreatitis with pancreatic duct stent placement reported significant decreases, by 10.4%, 
14.8%, and 52.3%, in the rates of PEP in patients treated with stent placement versus those 
without stent placement [78,79,85]. Although pancreatic duct stenting decreases the risk of 
PEP, it has not been shown to prevent it. Despite stent placement, pancreatitis occurs in 
2.0%–14% of patients [78,79,81,83,84], and some studies have failed to demonstrate a 
significant protective effect [59,83,84]. Eight RCTs, multiple prospective uncontrolled 
studies, and five meta-analyses have compared the rates of pancreatitis after ERCP with and 
without prophylactic pancreatic stent placement [86–90]. Prophylactic stent placement 
reduces the incidence of PEP, particularly in high-risk patients, and virtually eliminates the 
risk of severe pancreatitis. 
Many studies have criticized the absence of intent-to-treat analysis (i.e., patients with 
attempted but unsuccessful stent placement were excluded). However, a meta-analysis 
showed that the four RCTs used intent-to-treat principles by assuming that PEP developed 
in patients in whom the attempted prophylactic pancreatic stent placement failed, even 
when the clinical outcome was not stated in the original study. Despite the use of this 
approach, the odds ratio in the stent group was 0.44 compared with the controls and 
differed significantly in favor of stent placement [86]. On the basis of these results, 
prophylactic stent placement can be considered as the single most important advance in the 
past 15 years for the prevention of PEP in high-risk patients. Despite these findings, 
questions remain about when to place a prophylactic pancreatic stent, the type of stent to 
place, and the optimal follow-up period to ensure adequate removal. The incidence of 
adverse events associated with pancreatic stent placement is around 4% and must be 
considered in the decision-making process for the placement of a stent [86,91]. 
4.5 Biliary stone extraction  
In the setting of choledocholithiasis, endoscopic papillary balloon dilatation (EPBD), ES, and 
mechanical lithotripsy are techniques used to extract obstructing stones. Many studies have 
shown an increased rate of PEP with EPBD; the rates range from 4.9–20% with EPBD versus 
0.42–10% with ES [92–95]. Prospective trials support this observation, although it is difficult 
to generalize the findings given the many factors that contribute to procedural 
complications [96–100]. Balloon dilation may also be required in some clinical settings. If a 
patient has had a prior sphincterotomy and has limited remaining tissue for incision, 
balloon dilation may be necessary to enlarge the bile duct insertion and enable stone 
extraction. 
5. Patient-related risk factors associated with PEP 
Given the high risk of PEP in certain populations, identifying a clear indication is critical for 
reducing the complication rate. ERCP is riskiest in patients who need it the least [101,102]. 
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Large prospective trials have demonstrated that being female, being younger than 60–70 
years, and having suspected sphincter of Oddi dysfunction (SOD) or a recurrent or prior 
PEP are associated with a higher risk of PEP [6,9,15,24,45,87,103,104] (Table 1). However, 
there is some variability between studies. For example, one smaller trial suggested an age of 
<50 years as a significant risk factor [104]. A recent large retrospective study of 16 855 
patients reported that the highest rates of PEP occurred in patients with SOD, but the rate 
was not significantly higher in younger patients or in women [63]. Alternatively, a meta-
analysis evaluating five patient-related risk factors demonstrated relative risks of SOD of 
4.09 (95% CI, 1.93–3.12; P<0.001) and of being female of 2.23 (95% CI, 1.75–2.84; P<0.001) 
[87]. One study demonstrated a 10-fold increase in the risk of PEP in patients with SOD 
[105]. Some factors may be protective as well. The absence of chronic pancreatitis [57], 
presence of obesity [106], older age (>80 years) [107], and a history of alcohol consumption 
or cigarette smoking may be associated with a lower risk of PEP [108]. Proper patient 
selection and identification of patients at higher risk are the most effective means for 
reducing the incidence of PEP. 
6. Pharmacological agents evaluated for the prevention or reduction of PEP 
The effects of pharmacological agents on PEP have attracted much interest. Preventing 
cellular injury and pancreatic tissue auto-digestion may involve blocking the premature 
activation of proteolytic enzymes within the acinar cells [14,45,109–116]. Although 
conceptually straightforward, the goal of blocking this activation has been difficult to 
achieve. Multiple trials have been performed with the goal of reducing the incidence or 
severity of PEP. About 34  pharmacological agents and procedures (e.g., topical application 
of pharmacological agents injected or sprayed onto the papilla) have been evaluated for 
their potential to prevent PEP in controlled trials. Most clinical trials have been 
disappointing, and only a minority of studies has demonstrated benefit (Table 2-5) 
[26,29,37,39,40,53,54,58,87,117–175]. 
In two of five prospective trials, allopurinol was shown to decrease the incidence of PEP 
[119,120]. In these trials showing benefits, allopurinol was given in 300 mg or 600 mg doses 
15 h and 3 h before ERCP. When reviewing other studies of allopurinol, these effects were 
not significant in patients dosed on different 4 h and 1 h regimens and with varying dose 
concentrations of allopurinol [121–123]. This suggests that both the dose and timing of 
allopurinol administration are important in reducing the risk of PEP. 
Three meta-analyses have been published using data obtained from four prospective, 
randomized, placebo-controlled studies that compared rectally administered diclofenac or 
indomethacin at a dose of 100 mg versus placebo [124–126]. No statistical heterogeneity was 
detected between the studies. Two RCTs evaluated the effect of rectal administration of 100 
mg diclofenac immediately after the procedure [39,143], and the other two evaluated rectal 
administration of 100 mg indomethacin immediately before the procedure [144,145]. Both 
sets of studies showed similar results. Patients who were considered to be at high risk for 
PEP were included in both studies. Overall, PEP occurred in 20/456 (4.4%) patients in the 
treatment groups versus 57/456 (12.5%) patients in the placebo groups. The estimated 
pooled relative risk was 0.36 (95% CI, 0.22–0.60), and the number needed to treat to prevent 
one episode of PEP was 15. The administration of nonsteroidal anti-inflammatory drugs 
(NSAIDs) was associated with a similar decrease in the incidence of PEP regardless of risk. 
No adverse event attributable to NSAIDs has been reported. A trial evaluating diclofenac 50  
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Table 2. Randomized controlled trails of drugs that decrease inflammation evaluated for 
reduction or prevention of post-ERCP pancreatitis. 
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Table 3. Randomized controlled trails of drugs that interrupt the activity of proteases 
evaluated for reduction or prevention of post-ERCP pancreatitis. 
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Table 4. Randomized controlled trails of inhibitors of pancreatic secretion evaluated for 
reduction or prevention of post-ERCP pancreatitis. 
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Table 5. Randomized controlled trails of drugs that decrease Sphincter of Oddi Pressure and 
miscellaneous drugs evaluated for reduction or prevention of post-ERCP pancreatitis. 
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mg by mouth given 30–90 min before ERCP and up to 4–6 h after ERCP showed no decrease 
in the incidence of PEP [146]. A small clinical trial by Senol and colleagues found no 
significant difference in the incidence of PEP in patients given ERCP with the use of 75 mg 
of diclofenac by the intramuscular route plus intravenous (IV) hydration versus those given 
placebo and IV solutions [147]. According to the European Society of Gastrointestinal 
Endoscopy, no other drug prophylaxis has been proven to be effective against PEP as rectal 
NSAIDs [148]. 
Glyceryl trinitrate [141], hydrocortisone [130], and IL-10 [52] were shown to be beneficial in 
one RCT. However, studies with larger numbers of patients [26,54,140] found no significant 
effects of these treatments. Gabexate [160,161,163], octreotide [150,151], somatostatin 
[171,174], and ulinastatin [167] have all been reported to reduce the incidence of PEP. 
However, studies evaluating each of these agents using similar designs have reported no 
significant reduction in the incidence of PEP. These differences might be explained by 
differences in the selection and number of patients, clinical presentation, and timing of 
administration or dosage of the agents under investigation. 
7. Management of PEP 
Not all patients with pain and hyperamylasemia following ERCP have acute pancreatitis, 
and clinicians may have difficulty establishing the diagnosis. As a result, some patients with 
severe post-ERCP pancreatitis may not be identified in the early stages of their illness when 
aggressive hydration is most important. Some endoscopists may have difficulty 
acknowledging that post-ERCP pancreatitis has occurred, as this requires accepting that 
there has been a complication. A sense of guilt on the part of the clinician performing the 
procedure is understandable. However, delay in either the diagnosis or treatment of post-
ERCP pancreatitis may lead to adverse consequences. 
Post-ERCP pancreatitis should be managed as for other causes of acute pancreatitis. This is 
sometimes complicated by the difficulty distinguishing mild from severe disease in the early 
stages. The elevations in serum amylase and lipase levels do not always correlate with 
disease severity. 
Mild and moderate PEP usually resolve quickly with conservative therapy. Although there 
are no specific guidelines for the treatment of PEP, a recent study found that a protocol-
based management strategy was associated with less severe pancreatitis, shorter length of 
hospital stay, the need for fewer imaging studies, and less use of antibiotics [109,177].  
Practice guidelines for acute pancreatitis treatment are available and may be applicable to 
PEP as well [47]. In patients with persistent or severe PEP, two important markers of 
severity are multisystem organ failure and pancreatic necrosis, both of which require 
aggressive management [18]. Early identification of organ failure, pancreatic necrosis, 
perforation (especially in the setting of endoscopic sphincterotomy), biliary damage/leak 
and pancreatic fluid collections are important clinical branch points that may require more 
intensive intervention. Checking the levels of serum transaminases, amylase, and lipase is 
not routinely recommended after ERCP, but if assessed, postprocedure elevations occur 
often. These elevations are likely to be secondary to intermittent biliary, pancreatic, or 
papillary obstruction. In a recent study, 46% of patients had elevated liver test results after 
ERCP, but only 5.4% had PEP [110]. Asymptomatic elevation of liver markers is not an 
indication for a change in management and a repeat ERCP should be performed only with a 
clear indication. Although the use of enteral feeding during treatment of acute pancreatitis is 
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controversial, patients who are unlikely to resume oral nutrition within 5 days require 
nutritional support, which can be provided via total parenteral nutrition or enteral routes 
[177]. There appear to be some advantages to enteral feeding. A recent study found that 
initiating oral nutrition after mild acute pancreatitis with a low-fat soft diet appeared to be 
safe but did not shorten the length of hospitalization [111]. 
8. Conclusion 
Acute pancreatitis is a well-recognized and frequent complication that can occur in 1%–15% 
of patients undergoing ERCP. Clinical research to prevent PEP using depurate endoscopic 
techniques and pharmacological prophylaxis is intense and so far indicates that the use of 
NSAIDs and pancreatic stenting, coupled with appropriate selection of eligible patients and 
performed by an experienced endoscopist are the most effective preventive measures to 
reduce the incidence and severity this complication. 
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